Review Publication Confirms the Benefits of Highly Effective Oral Cancer Drug Xeloda(R) (capecitabine) Over Intravenous

(2) Decision Resources Survey.Oral chemotherapeutic agents: key success factors and reimbursement issues. A survey of US Oncologists and HMO pharmacy directors. June 2005

(3) Silberman G, Gupta S, Berkowitz N et al. Cost-effectiveness of capecitabine, continuous infusion 5-FU, gemcitabine and vinorelbine in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18: 422a (Abstr 1629).

(4) Baran RW, Dupere W, Susan M et al. Clinical and economic outcomes associated with metastatic breast cancer in managed care populations: capecitabine (Xeloda) versus comparison therapies. Proc Am Soc Clin Oncol 2002; 21: 1942.

    
    Media relations contacts:
    Julia Pipe
    International Communications Manager - Xeloda
    Roche
    Tel: +41-61-687-4376
    Mobile: +41(0)79-263-9715
    Email: julia.pipe@roche.com
    Nerea Hinzpeter
    ShireHealthPR
    Tel: +1-212-625-4178
    Mobile: +1-646-407-9015
    Email: nerea.hinzpeter@shirehealthpr.com

Media relations contacts: Julia Pipe; International Communications Manager - Xeloda, Roche, Tel: +41-61-687-4376, Mobile: +41(0)79-263-9715, Email: julia.pipe@roche.com; Nerea Hinzpeter, ShireHealthPR, Tel: +1-212-625-4178, Mobile: +1-646-407-9015, Email: nerea.hinzpeter@shirehealthpr.com